Shanghai & Xinjiang, China, 10 July 2025 — On July 10, the world’s first 5G remote autopilot robotic bronchoscopy preclinical cryoablation trial in animal models was successfully completed using the Trans-bronchial Surgical Robot system, developed by MicroPort® MedBot™.
The groundbreaking experiment was carried out by Professor Jiayuan Sun, Vice President of Shanghai Chest Hospital, and his team, in collaboration with the First Affiliated Hospital of Shihezi University in Xinjiang.
The experiment, spanning a physical distance of 4,000 kilometers, highlighted the capabilities of 5G technology in enabling real-time precision control. Operating from Shanghai, physicians at the Respiratory Endoscopy Center of Shanghai Chest Hospital remotely manipulated the robotic system located in Xinjiang. Through the high-speed, ultra-low-latency 5G network, the team overcame technical challenges associated with remote experimentation and successfully conducted precise cryoablation therapy on the test animals.
The Trans-bronchial Surgical Robot by MicroPort® MedBot™ integrates electromagnetic navigation and visual feedback, ensuring high stability and repeatability. Its most distinctive feature, an autopilot navigation through the intricate “bronchial tree”, allows the robot to reach targeted lesions with minimal intervention, enhancing both precision and safety while significantly reducing operation time.
This animal trial sets the stage for future advancements in remote interventional treatments. “This breakthrough brings us closer to realizing the vision of delivering advanced care to patients thousands of miles away,” said Professor Jiayuan Sun. “We will continue to advance these technologies and accelerate their transition into clinical practice.”
About MicroPort® MedBot™
Commenced its development for laparoscopic surgery robots in 2014, and officially established in Shanghai in 2015, Shanghai MicroPort MedBot (Group) Co., Ltd. ("MicroPort® MedBot™", stock code: 02252.HK), a subsidiary of MicroPort Scientific Corporation ("MicroPort®", stock code: 00853.HK), is currently the only surgical robot company in the world with businesses covering five promising subsectors of surgical robots, including endoscopy, orthopedics, vascular intervention, natural orifice surgery, and percutaneous puncture. At MicroPort® MedBot™, we are committed to meeting the growing demand for cutting-edge robotic surgery. By integrating advanced research on robotics, control algorithms, image-based navigation, and precision imaging, we provide comprehensive intelligent surgical solutions to prolong and reshape the lives of patients, lead the advancement of robotic surgery, and shape the era of intelligent surgery.
More information is available at: www.medbotsurgical.com/en